SLC24A2 and prostate cancer: Consistent with previous enrichment analysis of DEGs, SLC24A2 showed the abnormal expression in 17 cancers including bladder cancer (BLCA), prostate cancer (PRAD), and lung cancer (LUAD and LUSC) (Figure 6(a)).